We are pleased to announce the entry of Statuto Fiduciaria as a new shareholder, representing the subscribers of the SAFE – Simple Agreement for Future Equity – which has reached €500,000.
This transaction confirms the strong interest in the Hemera project from qualified stakeholders with a focus on innovation in the scientific and technological fields.
The funds raised will support ongoing research and development activities, as well as clinical product development. With this milestone, the company continues to advance its growth strategy, aiming to translate the promising laboratory results in nervous tissue regeneration into clinical applications.